High dose 17β-estradiol and the α-estrogen agonist PPT trigger apoptosis in human adrenal carcinoma cells but the β-estrogen agonist DPN does not

L. M. Prieto, J. W. Brown, Carlos Perez-Stable, L. M. Fishman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Previous studies have shown that high dose 17β-estradiol (10 -5 M) has a G2/M blocking effect in SW-13 human adrenal carcinoma cultures and strongly enhances apoptosis. To examine the differential effects of estrogen α and β-receptors in this system, we incubated SW-13 cells with specific α- and β-estrogen receptor agonists, PPT [4,4′,4″-(propyl-[1H]-pyraole-1,3,5-triyl) trisphenol] and DPN [2,3-bis (4-hydroxyphenyl) propionitrile], respectively (each at 10 -5 M). Flow cytometry was used to analyze the percentages of cells in various phases of the cell cycle [sub-G1 (apoptosis), G1, S, and G2/M] in each experimental condition. Exposure to 17β-estradiol for 48 hours increased apoptosis more than 5-fold (from 3.6 ± 0.5 to 20 ± 2.2% of cells; p < 0.01). The α-estrogen agonist PPT had a similar effect, increasing apoptosis to 22 ± 1.7% (p < 0.01), but the β-agonist DPN caused no change (3.6 ± 0.5 vs. 3.9 ± 0.8%). While estrogen and the α-estrogen agonist decrease apoptosis in this system, both of these compounds decreased the percentage of cells in G1 (from 59 ± 1.4% for control to 34 ± 2.3% for estrogen and 40 ± 2.0% for PPT; p < 0.01 for both agents relative to control); the β-agonist again had no effect. Estrogen was also found to block the cell cycle in G2/M, increasing it from 15 ± 0.4 to 21 ± 1.0% of cells (p < 0.01), but neither the α- nor β-estrogen agonists had any effect at this point in the cell cycle, indicating that the influence of estrogen was not likely to be either α- or β-receptor mediated. There was no apparent effect of any of these agents on DNA synthesis, as indicated by unchanged percentages of cells in S phase. These studies suggest that induction of apoptosis by estrogen in SW-13 human adrenal cortical carcinoma cultures is mediated by the α-receptor, but the G2/M blocking effect of estrogen is not likely to be related to either α or β mechanisms.

Original languageEnglish
Pages (from-to)311-314
Number of pages4
JournalHormone and Metabolic Research
Volume40
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

NAD
Estradiol
Estrogens
Cells
Apoptosis
Carcinoma
Cell Cycle
Adrenocortical Carcinoma
Flow cytometry
S Phase
Estrogen Receptors
Flow Cytometry
DNA

Keywords

  • Adrenal cancer
  • Apoptosis
  • DPN
  • Estrogen
  • PPT

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

High dose 17β-estradiol and the α-estrogen agonist PPT trigger apoptosis in human adrenal carcinoma cells but the β-estrogen agonist DPN does not. / Prieto, L. M.; Brown, J. W.; Perez-Stable, Carlos; Fishman, L. M.

In: Hormone and Metabolic Research, Vol. 40, No. 5, 01.05.2008, p. 311-314.

Research output: Contribution to journalArticle

@article{831835d0cd114c829081909c4ec38c39,
title = "High dose 17β-estradiol and the α-estrogen agonist PPT trigger apoptosis in human adrenal carcinoma cells but the β-estrogen agonist DPN does not",
abstract = "Previous studies have shown that high dose 17β-estradiol (10 -5 M) has a G2/M blocking effect in SW-13 human adrenal carcinoma cultures and strongly enhances apoptosis. To examine the differential effects of estrogen α and β-receptors in this system, we incubated SW-13 cells with specific α- and β-estrogen receptor agonists, PPT [4,4′,4″-(propyl-[1H]-pyraole-1,3,5-triyl) trisphenol] and DPN [2,3-bis (4-hydroxyphenyl) propionitrile], respectively (each at 10 -5 M). Flow cytometry was used to analyze the percentages of cells in various phases of the cell cycle [sub-G1 (apoptosis), G1, S, and G2/M] in each experimental condition. Exposure to 17β-estradiol for 48 hours increased apoptosis more than 5-fold (from 3.6 ± 0.5 to 20 ± 2.2{\%} of cells; p < 0.01). The α-estrogen agonist PPT had a similar effect, increasing apoptosis to 22 ± 1.7{\%} (p < 0.01), but the β-agonist DPN caused no change (3.6 ± 0.5 vs. 3.9 ± 0.8{\%}). While estrogen and the α-estrogen agonist decrease apoptosis in this system, both of these compounds decreased the percentage of cells in G1 (from 59 ± 1.4{\%} for control to 34 ± 2.3{\%} for estrogen and 40 ± 2.0{\%} for PPT; p < 0.01 for both agents relative to control); the β-agonist again had no effect. Estrogen was also found to block the cell cycle in G2/M, increasing it from 15 ± 0.4 to 21 ± 1.0{\%} of cells (p < 0.01), but neither the α- nor β-estrogen agonists had any effect at this point in the cell cycle, indicating that the influence of estrogen was not likely to be either α- or β-receptor mediated. There was no apparent effect of any of these agents on DNA synthesis, as indicated by unchanged percentages of cells in S phase. These studies suggest that induction of apoptosis by estrogen in SW-13 human adrenal cortical carcinoma cultures is mediated by the α-receptor, but the G2/M blocking effect of estrogen is not likely to be related to either α or β mechanisms.",
keywords = "Adrenal cancer, Apoptosis, DPN, Estrogen, PPT",
author = "Prieto, {L. M.} and Brown, {J. W.} and Carlos Perez-Stable and Fishman, {L. M.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1055/s-2008-1073141",
language = "English",
volume = "40",
pages = "311--314",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "5",

}

TY - JOUR

T1 - High dose 17β-estradiol and the α-estrogen agonist PPT trigger apoptosis in human adrenal carcinoma cells but the β-estrogen agonist DPN does not

AU - Prieto, L. M.

AU - Brown, J. W.

AU - Perez-Stable, Carlos

AU - Fishman, L. M.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Previous studies have shown that high dose 17β-estradiol (10 -5 M) has a G2/M blocking effect in SW-13 human adrenal carcinoma cultures and strongly enhances apoptosis. To examine the differential effects of estrogen α and β-receptors in this system, we incubated SW-13 cells with specific α- and β-estrogen receptor agonists, PPT [4,4′,4″-(propyl-[1H]-pyraole-1,3,5-triyl) trisphenol] and DPN [2,3-bis (4-hydroxyphenyl) propionitrile], respectively (each at 10 -5 M). Flow cytometry was used to analyze the percentages of cells in various phases of the cell cycle [sub-G1 (apoptosis), G1, S, and G2/M] in each experimental condition. Exposure to 17β-estradiol for 48 hours increased apoptosis more than 5-fold (from 3.6 ± 0.5 to 20 ± 2.2% of cells; p < 0.01). The α-estrogen agonist PPT had a similar effect, increasing apoptosis to 22 ± 1.7% (p < 0.01), but the β-agonist DPN caused no change (3.6 ± 0.5 vs. 3.9 ± 0.8%). While estrogen and the α-estrogen agonist decrease apoptosis in this system, both of these compounds decreased the percentage of cells in G1 (from 59 ± 1.4% for control to 34 ± 2.3% for estrogen and 40 ± 2.0% for PPT; p < 0.01 for both agents relative to control); the β-agonist again had no effect. Estrogen was also found to block the cell cycle in G2/M, increasing it from 15 ± 0.4 to 21 ± 1.0% of cells (p < 0.01), but neither the α- nor β-estrogen agonists had any effect at this point in the cell cycle, indicating that the influence of estrogen was not likely to be either α- or β-receptor mediated. There was no apparent effect of any of these agents on DNA synthesis, as indicated by unchanged percentages of cells in S phase. These studies suggest that induction of apoptosis by estrogen in SW-13 human adrenal cortical carcinoma cultures is mediated by the α-receptor, but the G2/M blocking effect of estrogen is not likely to be related to either α or β mechanisms.

AB - Previous studies have shown that high dose 17β-estradiol (10 -5 M) has a G2/M blocking effect in SW-13 human adrenal carcinoma cultures and strongly enhances apoptosis. To examine the differential effects of estrogen α and β-receptors in this system, we incubated SW-13 cells with specific α- and β-estrogen receptor agonists, PPT [4,4′,4″-(propyl-[1H]-pyraole-1,3,5-triyl) trisphenol] and DPN [2,3-bis (4-hydroxyphenyl) propionitrile], respectively (each at 10 -5 M). Flow cytometry was used to analyze the percentages of cells in various phases of the cell cycle [sub-G1 (apoptosis), G1, S, and G2/M] in each experimental condition. Exposure to 17β-estradiol for 48 hours increased apoptosis more than 5-fold (from 3.6 ± 0.5 to 20 ± 2.2% of cells; p < 0.01). The α-estrogen agonist PPT had a similar effect, increasing apoptosis to 22 ± 1.7% (p < 0.01), but the β-agonist DPN caused no change (3.6 ± 0.5 vs. 3.9 ± 0.8%). While estrogen and the α-estrogen agonist decrease apoptosis in this system, both of these compounds decreased the percentage of cells in G1 (from 59 ± 1.4% for control to 34 ± 2.3% for estrogen and 40 ± 2.0% for PPT; p < 0.01 for both agents relative to control); the β-agonist again had no effect. Estrogen was also found to block the cell cycle in G2/M, increasing it from 15 ± 0.4 to 21 ± 1.0% of cells (p < 0.01), but neither the α- nor β-estrogen agonists had any effect at this point in the cell cycle, indicating that the influence of estrogen was not likely to be either α- or β-receptor mediated. There was no apparent effect of any of these agents on DNA synthesis, as indicated by unchanged percentages of cells in S phase. These studies suggest that induction of apoptosis by estrogen in SW-13 human adrenal cortical carcinoma cultures is mediated by the α-receptor, but the G2/M blocking effect of estrogen is not likely to be related to either α or β mechanisms.

KW - Adrenal cancer

KW - Apoptosis

KW - DPN

KW - Estrogen

KW - PPT

UR - http://www.scopus.com/inward/record.url?scp=45549099394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549099394&partnerID=8YFLogxK

U2 - 10.1055/s-2008-1073141

DO - 10.1055/s-2008-1073141

M3 - Article

VL - 40

SP - 311

EP - 314

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 5

ER -